NBY · Novabay Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | $3.30M | $6.83M | $6.62M | $2.78M | $3.97M |
| Gross Profit | - | $6.48M | $7.89M | $7.78M | $5.64M | $5.96M |
| R&D | - | $42.0K | $68.0K | $174.0K | $44.0K | $285.0K |
| SG&A | $7.58M | $7.38M | $6.33M | $7.49M | $7.24M | $5.93M |
| Total Operating Expenses | $8.44M | $12.32M | $15.49M | $22.20M | $14.51M | $12.39M |
| D&A | - | $40.0K | $51.0K | $120.0K | $119.0K | $51.0K |
| Operating Income | ($8.44M) | ($5.84M) | ($7.60M) | ($14.42M) | ($8.86M) | ($6.43M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | - | $0 | $0 | $5.0K |
| Net Income | ($22.14M) | ($7.22M) | ($9.64M) | ($10.61M) | ($5.82M) | ($11.04M) |
| EPS - Basic | ($3.80) | ($12.65) | ($693.00) | ($1767.50) | ($918.75) | ($1898.75) |
| EPS - Diluted | - | - | - | - | - | ($1898.75) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.96M | $430.0K | $3.13M | $5.36M | $7.50M | $11.95M |
| Accounts Receivable | - | - | $1.97M | - | - | - |
| Inventory | - | $765.0K | $2.88M | $3.44M | $3.22M | $608.0K |
| Accounts Payable | $257.0K | $623.0K | $1.13M | $1.08M | $1.04M | $302.0K |
| Current Assets | $8.68M | $1.94M | $7.15M | $11.33M | $13.17M | $14.24M |
| Total Assets | $9.04M | $3.42M | $9.03M | $16.40M | $23.98M | $15.24M |
| Current Liabilities | $1.14M | $2.84M | $4.28M | $4.26M | $3.44M | $2.83M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $31.86M | $3.55M | $5.72M | $5.84M | $13.81M | $2.92M |
| Stockholders' Equity | ($23.18M) | ($129.0K) | $3.31M | $10.55M | $10.17M | $12.32M |
| Retained Earnings | ($210.41M) | ($183.46M) | ($174.85M) | ($158.15M) | ($141.89M) | ($136.06M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.50M) | ($5.18M) | ($4.13M) | ($6.65M) | ($9.19M) | ($4.72M) |
| Investing Cash Flow | - | $1.06M | ($19.0K) | ($112.0K) | ($12.04M) | ($26.0K) |
| Financing Cash Flow | $4.62M | $1.50M | $1.91M | $4.63M | $16.79M | $9.76M |
| CapEx | - | $6.0K | $19.0K | $112.0K | $52.0K | $26.0K |
| Free Cash Flow | - | ($5.19M) | ($4.15M) | ($6.77M) | ($9.24M) | ($4.75M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | 0.72 | 0.43 | 0.64 | 1.59 | 0.43 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -245.1% | -211.0% | -106.7% | -64.7% | -24.3% | -72.4% |
| Return on equity | 95.5% | 5599.2% | -290.9% | -100.5% | -57.3% | -89.6% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 7.60 | 0.68 | 1.67 | 2.66 | 3.83 | 5.03 |
| Quick ratio | 7.60 | 0.41 | 1.00 | 1.85 | 2.89 | 4.81 |
| Cash ratio | 6.97 | 0.15 | 0.73 | 1.26 | 2.18 | 4.22 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -0.39 | -26.53 | 2.73 | 1.55 | 2.36 | 1.24 |
| Liabilities / Assets | 3.53 | 1.04 | 0.63 | 0.36 | 0.58 | 0.19 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | 4.31 | 2.37 | 1.93 | 0.86 | 6.53 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | 85d | 154d | 189d | 423d | 56d |
| Days payable outstanding | - | 69d | 60d | 60d | 137d | 28d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | 12156.5x |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | -17.9% | 1.5% | 37.8% | -5.3% | 22.7% |
| Operating income growth (YoY) | -44.5% | 23.1% | 47.3% | -62.7% | -37.9% | 31.6% |
| Net income growth (YoY) | -206.5% | 25.1% | 9.1% | -82.1% | 47.2% | -14.3% |
| EPS growth (YoY) | - | - | - | - | - | -395472.9% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | -25.0% | 38.7% | 26.8% | -94.7% | 40.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -17865.9% | - | -68.6% | 3.8% | -17.4% | 1166.0% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NovaBay Pharmaceuticals against the 5 most active filers in the same SIC group.
Dividends
$4.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Sep 30, 2025 | $4.0000 |